Sherika Cowan
Psychiatric/Mental Health · Memphis, XXNPI 1295483022
Payments from drug & device makers
Across 38 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$252
- AbbVie$206
- Johnson & Johnson$136
- Indivior Inc.$105
- Otsuka America Pharmaceutical, Inc.$80
- Lundbeck LLC$78
- plus $41 from 2 others
What the payments were for
- Food & beverage$81891%
- Education$819%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 11 | $252 |
| AbbVie | 9 | $206 |
| Johnson & Johnson | 4 | $136 |
| Indivior Inc. | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Lundbeck LLC | 3 | $78 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
How this compares
Too few psychiatric/mental health providers in XXto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 126 | $363,867 |
| Invega TrinzaPaliperidone Palmitate | 21 | $177,528 |
| AristadaAripiprazole Lauroxil | 27 | $80,396 |
| Abilify MaintenaAripiprazole | 23 | $52,025 |
| CaplytaLumateperone Tosylate | 14 | $23,051 |
| VraylarCariprazine Hcl | 12 | $17,367 |
| Aripiprazole | 114 | $10,315 |
| Asenapine Maleate | 18 | $7,176 |
| Lurasidone Hcl | 46 | $6,647 |
| Haloperidol Decanoate | 159 | $4,156 |
| Ziprasidone Hcl | 21 | $3,953 |
| Benztropine Mesylate | 318 | $3,813 |
| Hydroxyzine Hcl | 128 | $3,428 |
| Fluphenazine Decanoate | 169 | $3,097 |
| Quetiapine Fumarate | 143 | $2,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $136 | $541,395147 claims |
| Alkermes, Inc.Aristada | $252 | $80,39627 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $80 | $52,02523 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $15 | $23,05114 claims |
| AbbVieVraylar | $206 | $17,36712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health providers in XXon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.